

Organophotoredox Hydrodefluorination of Trifluoromethylarenes with Translational Applicability to Drug Discovery

Jeroen B. I. Sap, Natan J. W. Straathof, Thomas Knauber, Claudio F. Meyer, Maurice Médebielle, Laura Buglioni, Christophe Genicot, Andrés A. Trabanco, Timothy Noël, Christopher W. am Ende, and Véronique Gouverneur*



Cite This: *J. Am. Chem. Soc.* 2020, 142, 9181–9187



Read Online

ACCESS |



Metrics & More



Article Recommendations




Supporting Information

ABSTRACT: Molecular editing such as insertion, deletion, and single atom exchange in highly functionalized compounds is an aspirational goal for all chemists. Here, we disclose a photoredox protocol for the replacement of a single fluorine atom with hydrogen in electron-deficient trifluoromethylarenes including complex drug molecules. A robustness screening experiment shows that this reductive defluorination tolerates a range of functional groups and heterocycles commonly found in bioactive molecules. Preliminary studies allude to a catalytic cycle whereby the excited state of the organophotocatalyst is reductively quenched by the hydrogen atom donor, and returned in its original oxidation state by the trifluoromethylarene.

Fluorine-containing molecules have found applications in the pharmaceutical and agrochemical sector because of the thermodynamic and kinetic stability of C–F σ -bonds,¹ a property offering protection against enzymatic metabolism.¹ Today, pharmacophores often bear a trifluoromethyl or difluoromethyl motif in an aromatic system, thereby increasing the demand for methods to install or interchange these groups in a late-stage fashion.² In this context, molecular editing enabling precision hydrodefluorination (HDF) of trifluoromethylarenes into difluoromethylarenes for applications in drug discovery remains a highly challenging endeavor because the bond dissociation energy (BDE) of C–F bonds decreases as fluorine substitution takes place (Scheme 1A).^{3,4a} Pioneering studies have reported strategies employing boron, silylium or phosphine adducts,⁵ and (transition) metals, but uncontrolled defluorination could not be avoided for many of these processes.⁶ Jui and co-workers demonstrated that hydrofluorination is accomplished with cesium formate and the Miyake phenoxazine photocatalyst under blue light activation (Scheme 1B).^{7a} This protocol is applicable to unactivated trifluoromethylarenes adorned with electron-donating groups. Despite these significant advances in the field, HDF of highly activated trifluoromethylarenes featuring electron-withdrawing groups to access difluoromethylarenes has not been accomplished. This is unexpected because most tri- and difluoromethylated drugs feature the CF₃ or CF₂H group on electron-poor arenes due to their higher resistance to oxidation and defluorination in comparison with electron-rich counterparts.⁸

Mechanistic studies reported in 1997 by Savéant and Thiébaud provided useful information on the electrochemical reductive cleavage of C–F bonds for 4-cyanofluorotoluenes 1a–c and trifluoromethylbenzene.^{4a} The process involves fluoride expulsion from a radical anion, followed by reduction of the resulting neutral radical, and protonation. As expected, the standard reduction potential for the formation of the

Scheme 1. Hydrodefluorination of Trifluoromethylarenes in Drug Discovery




Received: April 14, 2020

Published: May 7, 2020



radical anion decreases from **1a** to **1c**, although these are closely spaced (narrow redox window), while the instability of the radical anion toward fluoride mesolytic cleavage increases. Facile exhaustive defluorination is observed experimentally, the challenge at hand for these highly activated substrates (Scheme 2).

Scheme 2. Electrochemical Reductive Cleavage of Trifluoromethylarenes: Standard Reduction Potentials ($E_{1/2}$ vs Standard Calomel Electrode (SCE) in DMF) and Cleavage Rate Constants




$E_{1/2}$ (V vs SCE in DMF).^{4b}

Preliminary experiments with 4-(trifluoromethyl)benzonitrile **1a** showed that no product **1b** was formed applying the protocols of Prakash or Lalic (Table 1, entries 1 and 2).⁶ Moreover, the conditions applied for known photoredox defluorination using trifluoromethylarenes led mainly to recovery of starting material (Table 1, entries 3–5).^{7a–c} The more electrophilic nature of the difluorinated benzylic radical derived from electron-deficient **1a** compared to electron-rich substrates encouraged a study examining hydrogen atom donors (HAD) other than cesium formate.^{7a} Gratifyingly, the reaction of **1a** in the presence of 2.5 mol % *fac*-Ir(ppy)₃, 4-hydroxythiophenol (4-HTP) and a combination of 2,2,6,6-tetramethylpiperidine (TMP) and 1,2,2,6,6-pentamethylpiperidine (PMP) in 1,2-dichloroethane (DCE) under visible light activation (blue LED) gave **1b** in 53% with 5:1 selectivity (**1b**:**1c**). The fully reduced 4-methylbenzonitrile product was not detected (Table 1, entry 6). Organophotocatalyst 2,4,5,6-tetrakis(diphenylamino)isophthalonitrile (4-DPA-IPN, 2.5 mol %) was a suitable metal-free replacement for *fac*-Ir(ppy)₃ affording **1b** in 62% yield with similar selectivity (Table 1, entry 7). Lowering catalyst loading did not affect the reaction outcome (65% yield, **1b**:**1c** = 5:1) (Table 1, entry 8). Hydrogen atom donors including thiols other than 4-HTP, 1,4-cyclohexadiene, the Hantzsch ester, (Me₃Si)₃SiH, or CsOCOH were less or not suitable under otherwise similar reaction conditions (Table 1, entries 9–17). The photocatalyst, HAD, base, and blue light are essential components for this transformation to proceed (Table 1, entries 18–23).

With the optimal reaction conditions in hand, we explored the generality of this HDF reaction (Scheme 3). 2-(Trifluoromethyl)benzonitrile gave **2b** in 63% yield and >20:1 selectivity favoring CF₂H. Additional functionalities on the aromatic ring including fluorine, methoxy, or acetamide were tolerated (**3b**, **5b**, and **7b**, 42–88%) with high selectivity for CF₂H (>10:1). Methyl and ethyl 4-(trifluoromethyl)benzoate **4a** and **8a** with a carboxylic ester instead of a cyano group were transformed into difluoromethylated analogues **4b** and **8b** in moderate yields (30% and 40%) and 3:1 selectivity. When the catalyst loading was increased to 2.5 mol %, the yield

Table 1. Experiments for the Hydrodefluorination of 4-(Trifluoromethyl)benzonitrile **1a**




Entry	Alterations to conditions	Yield ^d (ratio 1b : 1c)
1	Mg ⁰ (30 equiv), H ₂ O/AcOH/DMSO	0%
2	Pd(OAc) ₂ (3 mol %), CuF ₂ (20 mol %), 2-pyridone (5 mol %), KOSiMe ₃ (7.0 equiv), DMF, 45 °C, then <i>t</i> BuOH (2.0 equiv), 60 °C	0%
3 ^b	Miyake Phenoxazine (2 mol %), II (3 equiv), blue LED, DMSO, 50 °C, 24 h	4% (2:1)
4 ^c	<i>fac</i> -Ir(ppy) ₃ (1.0 mol %), TMP (2.0 equiv), HBPIn (3.0 equiv), blue LED, DCE, rt, 24 h	0%
5 ^d	PTH (10 mol %), VI (10 mol %), II (3 equiv), blue LED, 5% H ₂ O/DMSO, rt, 24 h	0%
6	<i>fac</i> -Ir(ppy) ₃ (2.5 mol %)	53% (5:1)
7	4-DPA-IPN (2.5 mol %)	62% (5:1)
8	No alteration	65% (5:1)
9	I (6 equiv) instead of III	trace
10	II (6 equiv) instead of III	trace
11	IV (6 equiv) instead of III	0%
12	V (6 equiv) instead of III	15% (5:1)
13	VI (6 equiv) instead of III	4% (8:1)
14	VII (6 equiv) instead of III	4% (8:1)
15	VIII (6 equiv) instead of III	5% (8:1)
16	IX (6 equiv) instead of III	22% (7:1)
17	X (6 equiv) instead of III	22% (7:1)
18	no PMP	51% (5:1)
19	no TMP	31% (>20:1)
20	no TMP and no PMP	0%
21	no light	0%
22	no 4-HTP	0%
23	no photocatalyst	0%

^aCombined yields of **1b** and **1c** determined by ¹⁹F NMR using 4-fluoroanisole as internal standard; the ratio of **1b**:**1c** is given in parentheses. ^bReaction carried out on **14a**. ^cConditions of ref **7c** with no alkene. ^dConditions of ref **7b** with no alkene. PTH = 10-phenyl-10H-phenothiazine. BDE values for arylthiols from ref **9**.

was improved (**8b**, 63%), but the product resulting from double reductive defluorination was formed preferentially

Scheme 3. Scope of HDF



^aYields and CF₂H/CH₂F ratio determined by quantitative ¹⁹F NMR spectroscopy using 4-fluoroanisole as internal standard. Yields of isolated products (RCF₂H only) are given in parentheses. ^b2.5 mol % 4-DPA-IPN. ^cSolvent is DCE/DMSO (19:1, v/v, c = 0.025 M).

(8b:8c = 1:2). Unprotected sulfonamide **6b** was within reach with excellent selectivity.

Complex molecules of biological relevance were examined next. Bicalutamide, a drug used to treat prostate cancer, underwent reductive defluorination affording **9b** isolated in 43% yield and 10:1 CF₂H/CH₂F selectivity.¹⁰ The doubly trifluoromethylated cannabinoid receptor agonist BAY 59-3074 **10a** reacted exclusively at the arene. An analogue of Enobosarm featuring three trifluoromethylaryl groups served the purpose to investigate a more complex case of “arene versus arene” chemoselectivity.¹¹ Hydrodefluorination occurred with excellent CF₂H/CH₂F selectivity (>20:1) at a single site, leaving the 3,5-bis-trifluoromethylarene motif untouched (**11b**, 53%); this result corroborates a control


experiment that demonstrated that 3,5-bis-trifluoromethylbenzene was unreactive under our reaction conditions. Bendroflumethiazide **12a**, a drug used for mild heart failure and hypertension via vasodilation,¹² was also subjected to C–F bond reduction. Our protocol, slightly modified in order to solubilize the starting material (solvent mixture of DCE/DMSO), gave CF₂H-bendroflumethiazide **12b** in 56% yield although with decreased selectivity (CF₂H/CH₂F ratio = 4:1). This result is significant because sulfonamides and/or amines can coordinate some metals, rendering late-stage cross-coupling strategies toward aryl–CF₂H bond construction more challenging.¹³ Enzalutamide, a hormonal therapy drug used to treat prostate cancer, also underwent HDF. This reaction yielded with excellent selectivity the difluoromethylated analogue **13b** isolated in 40% yield. The usefulness of this HDF protocol was further illustrated with the synthesis of **14b**, a molecule with strong androgen receptor binding affinity *in vivo*.¹⁴ This biologically relevant compound was previously prepared in eight steps.¹⁵ With our protocol, **14b** was obtained in two steps; the precursor **14a** was prepared in one step from commercially available materials,¹⁶ and HDF gave **14b** isolated in 60% yield. Alternative photoredox HDF protocols were not effective.¹⁷

Given the relevance of this novel HDF methodology for drug discovery, we conducted a robustness screening experiment to gain further information on its tolerance to various pharmacophores and functionalities (Scheme 4).¹⁸ Common functional groups compatibility was investigated with para-substituted toluenes **A**, revealing tolerance to bromine, amine, alcohol, carboxylic acid, and aldehyde functionalities. Next, a range of 2-pyridines **B**, 5-pyrimidines **C**, 3-pyridazines **D**, and 2-pyrazines **E** were subjected to screening. While 2-pyridines and 5-pyrimidines were broadly tolerated, 3-pyridazines and 2-pyrazines more often prevented hydrodefluorination. Isoxazoles **G** and pyrazoles **H** with various substitution patterns were well accepted. In addition, fused heteroarenes such as pyrazolopyridines **F**, benzooxazoles **I**, benzothiazoles **J**, indazoles **K**, and benzimidazoles **L** did not hamper the HDF of **1a**, a benefit considering the frequency of these motifs in modern pharmaceutical drugs.¹⁹ Many of the heterocycles investigated in this study could deactivate transition-metal catalysts by coordination,^{20,21} and the HDF offers an alternative to these methods.



Continuous-flow chemistry was considered to scale-up the HDF of **1a** (Scheme 5).²² The first reactions were performed in a microflow system made of a perfluoroalkoxyalkane capillary (internal diameter = 0.5 mm; internal volume = 2.0 mL) on a scale similar to batch (0.2 mmol); **1b** was obtained in 69% yield with 5:1 selectivity (CF₂H/CH₂F), within a 15 min residence time (*t_R*) at a flow rate of 0.133 μL/min. Additionally, **13b** (0.2 mmol) was isolated in 25% yield with 10:1 selectivity after a 7.5 min *t_R* at a flow rate of 0.266 μL/min. Starting with 2.5 g of **1a** (14.6 mmol), 1.4 g of **1b** (5:1) was produced in a 15 min *t_R* at a flow rate of 0.133 μL/min.

Various experiments were performed to gain preliminary insight on the mechanism of this transformation (Scheme 6).

A radical scavenger experiment performed with TEMPO led to the formation of adduct **15** (Scheme 6A). When the reaction of **1a** was carried out in the presence of styrene and 4-HTP, **16** was obtained in 56% yield (Scheme 6A). These data are consistent with the formation of a benzylic radical species formed by mesolytic C–F bond cleavage of a radical anion. Deuterium was incorporated in the product (40% yield, H/D


Scheme 4. Additive-Based Screening^a

^aAll reactions were performed on 2.5 μmol scale in a 96-well plate suited for photoredox chemistry. Crude mixtures were analyzed by GC-FID/MS.¹⁶

Scheme 5. Photoredox Hydrodefluorination under Continuous-Flow Conditions^a

^aYields of isolated products.

ratio of 3:2) when *d*₂-4-HTP was used instead of 4-HTP, indicating that 4-HTP is a plausible HAD in this reaction (Scheme 6A). Stern–Volmer luminescence quenching experiments provided additional information (Scheme 6B). We found that the combination of 4-HTP and TMP (1:1) quenches *PCⁿ; this is in contrast to TMP, PMP, CsOCOH or (TMS)₃SiH. The inability of **1a** to quench the excited state of

Scheme 6. (A) Mechanistic Experiments;^a (B) Stern–Volmer Luminescence Quenching Studies; (C) Proposed Reaction Mechanism

^aYields determined by quantitative ¹⁹F NMR using 4-fluoroanisole as internal standard.

the photocatalyst *PCⁿ advocates against an oxidative quenching cycle whereby the radical anion **17** would result from SET involving *PCⁿ/PCⁿ⁺¹ (−1.28 V).²³ These preliminary findings led us to propose the reductive quenching cycle shown in Scheme 6C as a plausible mechanistic pathway. Irradiation with light affords the excited state catalyst *PC. Under basic conditions, deprotonation of 4-HTP leads to a thiolate **A** capable of reductive quenching of *PC, a process yielding the corresponding thiyl radical **B**,²⁴ and the reduced photocatalyst (PCⁿ/PCⁿ⁻¹ = −1.52 V).²³ In this scenario, the substrate acts as the oxidant to return the photocatalyst to its native oxidation state with release of the radical anion species that undergoes mesolytic cleavage of fluoride.²⁵ This latter process leads to the C-centered difluorobenzyl radical **18** which is trapped by 4-HTP affording **1b**.

In conclusion, the reductive defluorination of electron-poor trifluoromethylarenes is accomplished under basic conditions

with 2,4,5,6-tetrakis(diphenylamino)isophthalonitrile as the organophotocatalyst,²⁶ 4-hydroxythiophenol as the HAD, and blue light. This operationally simple protocol tolerates a wide range of functional groups and heteroarenes frequently seen in medicinal chemistry programs, and allows the direct conversion of complex trifluoromethylated drugs into their difluoromethyl analogues. Mechanistic studies allude to a catalytic cycle whereby the photocatalyst is reduced by the HAD and returned in its native oxidation state by the trifluoromethylarene that acts as oxidant.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/jacs.0c03881>.

Additional optimization, mechanistic data, cyclic voltammetry, experimental procedures and analytical data (¹H, ¹⁹F, ¹³C NMR, high resolution mass spectrometry) for all new compounds (PDF)

■ AUTHOR INFORMATION

Corresponding Author

Véronique Gouverneur – Chemistry Research Laboratory, University of Oxford, Oxford OX1 3TA, United Kingdom; orcid.org/0000-0001-8638-5308; Email: veronique.gouverneur@chem.ox.ac.uk

Authors

Jeroen B. I. Sap – Chemistry Research Laboratory, University of Oxford, Oxford OX1 3TA, United Kingdom

Natan J. W. Straathof – Chemistry Research Laboratory, University of Oxford, Oxford OX1 3TA, United Kingdom

Thomas Knauber – Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States; orcid.org/0000-0002-3354-3322

Claudio F. Meyer – Chemistry Research Laboratory, University of Oxford, Oxford OX1 3TA, United Kingdom; Discovery Chemistry, Janssen Research and Development, Toledo E-45007, Spain

Maurice Médebielle – Univ. Lyon, Université Lyon I, CNRS, INSA, CPE-Lyon, ICBMS, UMR 5246, 69622 Villeurbanne cedex, France; orcid.org/0000-0002-6032-4790

Laura Buglioni – Micro Flow Chemistry and Synthetic Methodology, Department of Chemical Engineering and Chemistry, Eindhoven University of Technology, Helix 5600 MB, Eindhoven, The Netherlands

Christophe Genicot – Global Chemistry, UCB New Medicines, UCB Biopharma Sprl, 1420 Braine-L'Alleud, Belgium; orcid.org/0000-0002-8468-6681

Andrés A. Trabanco – Discovery Chemistry, Janssen Research and Development, Toledo E-45007, Spain; orcid.org/0000-0002-4225-758X

Timothy Noël – Micro Flow Chemistry and Synthetic Methodology, Department of Chemical Engineering and Chemistry, Eindhoven University of Technology, Helix 5600 MB, Eindhoven, The Netherlands; orcid.org/0000-0002-3107-6927

Christopher W. am Ende – Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States; orcid.org/0000-0001-8832-9641

Complete contact information is available at: <https://pubs.acs.org/doi/10.1021/jacs.0c03881>

Notes

The authors declare the following competing financial interest(s): T.K. and C.W.A. are employees of Pfizer Inc.; C.F.M. and A.A.T. are employees of Janssen; C.G. is an employee of UCB Biopharma Sprl.

■ ACKNOWLEDGMENTS

This project has received funding from the Engineering and Physical Sciences Research Council (EP/N509711/1) (J.B.I.S.), European Union's Horizon 2020 research and innovation program under Marie Skłodowska-Curie Grant Agreement 721902 (C.F.M.) and 840724 (L.B.). Gloria Rosetto (Williams group, Oxford) and Gabriele Laudadio (Eindhoven) are acknowledged for assistance with the deuteration and cyclic voltammetry experiments, respectively.

■ REFERENCES

- (1) (a) Müller, K.; Faeh, C.; Diederich, F. Fluorine in Pharmaceuticals: Looking Beyond Intuition. *Science* **2007**, *317*, 1881–1886. (b) Purser, S.; Moore, P. R.; Swallow, S.; Gouverneur, V. Fluorine in Medicinal Chemistry. *Chem. Soc. Rev.* **2008**, *37*, 320–330. (c) Meanwell, N. A. Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design. *J. Med. Chem.* **2018**, *61*, 5822–5880. (d) Wang, J.; Sánchez-Roselló, M.; Aceña, J. L.; del Pozo, C.; Sorochinsky, A. E.; Fustero, S.; Soloshonok, V. A.; Liu, H. Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011). *Chem. Rev.* **2014**, *114*, 2432–2506. (e) Clayden, J. Fluorinated compounds present opportunities for drug discovery. *Nature* **2019**, *573*, 37–38.
- (2) (a) Sessler, C. D.; Rahm, M.; Becker, S.; Goldberg, J. M.; Wang, F.; Lippard, S. J. CF₂H, a Hydrogen Bond Donor. *J. Am. Chem. Soc.* **2017**, *139*, 9325–9332. (b) Yerien, D. E.; Barata-Vallejo, S.; Postigo, A. Difluoromethylation reactions of organic compounds. *Chem. - Eur. J.* **2017**, *23*, 14676–14701. (c) Rong, J.; Ni, C.; Hu, J. Metal-Catalyzed Direct Difluoromethylation Reactions. *Asian J. Org. Chem.* **2017**, *6*, 139–152. (d) Lu, Y.; Liu, C.; Chen, Q.-Y. Recent Advances in Difluoromethylation Reaction. *Curr. Org. Chem.* **2015**, *19*, 1638–1650.
- (3) For seminal examples on C(sp³)-F and C(sp²)-F functionalization, see: (a) Senaweera, S. M.; Weaver, J. D. Selective Perfluoro- and Polyfluoroarylation of Meldrum's Acid. *J. Org. Chem.* **2014**, *79*, 10466–10476. (b) Khaled, M. B.; El Mokadem, R. K.; Weaver, J. D., III Hydrogen bond directed photocatalytic hydrodefluorination: overcoming electronic control. *J. Am. Chem. Soc.* **2017**, *139*, 13092–13101. (c) Xu, L.; Zhang, Q.; Xie, Q.; Huang, B.; Dai, J. J.; Xu, J.; Xu, H. J. Pd-catalyzed defluorination/arylation of α -trifluoromethyl ketones via consecutive β -F elimination and C-F bond activation. *Chem. Commun.* **2018**, *54*, 4406–4409. (d) Nishimine, T.; Taira, H.; Tokunaga, E.; Shiro, M.; Shibata, N. Enantioselective Trichloromethylation of MBH-Fluorides with Chloroform Based on Silicon-assisted C-F Activation and Carbanion Exchange Induced by a Ruppert-Prakash Reagent. *Angew. Chem., Int. Ed.* **2016**, *55*, 359–363. (e) Pigeon, X.; Bergeron, M.; Barabé, F.; Dubé, P.; Frost, H. N.; Paquin, J. F. Activation of Allylic C-F bonds: Palladium-Catalyzed Allylic Amination of 3,3-Difluoropropenes. *Angew. Chem., Int. Ed.* **2010**, *49*, 1123–1127. (f) Hamel, J. D.; Paquin, J. F. Activation of C-F bonds α to C-C multiple bonds. *Chem. Commun.* **2018**, *54*, 10224–10239. (g) Paquin, J. F. Synthesis of Monofluoroalkenes via the Activation of Allylic C-F Bonds: A Novel Route to β -Aminofluoroalkenes Using Pd-Catalyzed Allylic Amination Reactions of 3,3-Difluoropropenes. *Synlett* **2011**, *2011*, 289–293. (h) Haufe, G.; Suzuki, S.; Yasui, H.; Terada, C.; Kitayama, T.; Shiro, M.; Shibata, N. C-F Bond Activation of Unactivated Aliphatic Fluorides: Synthesis of Fluoromethyl-3,5-diaryl-2-oxazolidinones by Desymmetrization of 2-Aryl-1,3-difluoropropan-2-ols. *Angew. Chem., Int. Ed.* **2012**, *51*, 12275–12279. (i) Hazari, A.; Gouverneur, V.;

Brown, J. M. Palladium-Catalyzed Substitution of Allylic Fluorides. *Angew. Chem., Int. Ed.* **2009**, *48*, 1296–1299. (j) Blessley, G.; Holden, P.; Walker, M.; Brown, J. M.; Gouverneur, V. Palladium-Catalyzed Substitution and Cross-Coupling of Benzylic Fluorides. *Org. Lett.* **2012**, *14*, 2754–2757. For selected reviews on C–F bond activation, see: (k) Amii, H.; Uneyama, K. C–F bond activation in organic synthesis. *Chem. Rev.* **2009**, *109*, 2119–2183. (l) Ahrens, T.; Kohlmann, J.; Ahrens, M.; Braun, T. Functionalization of Fluorinated Molecules by Transition-Metal-Mediated C–F Bond Activation to Access Fluorinated Building Blocks. *Chem. Rev.* **2015**, *115*, 931–972. (m) Senaweera, S. M.; Singh, A.; Weaver, J. D. Photocatalytic Hydrodefluorination: Facile Access to Partially Fluorinated Aromatics. *J. Am. Chem. Soc.* **2014**, *136*, 3002–3005.

(4) (a) Andrieux, C. P.; Combella, C.; Kanoufi, F.; Savéant, J.; Thiébaud, A. Dynamics of Bond Breaking in Ion Radicals. Mechanisms and Reactivity in the Reductive Cleavage of Carbon-Fluorine Bonds of Fluoromethylarenes. *J. Am. Chem. Soc.* **1997**, *119*, 9527–9540. (b) Clavel, P.; Lessene, G.; Biran, C.; Bordeau, M.; Roques, N.; Trévin, S.; Montauzon, D. D. Selective electrochemical synthesis and reactivity of functional benzylic fluorosilylsynthons. *J. Fluorine Chem.* **2001**, *107*, 301–310.

(5) (a) Ferraris, D.; Cox, C.; Anand, R.; Lectka, T. C–F Bond Activation by Aryl Carbocations: Conclusive Intramolecular Fluoride Shifts between Carbon Atoms in Solution and the First Examples of Intermolecular Fluoride Ion Abstractions. *J. Am. Chem. Soc.* **1997**, *119*, 4319–4320. (b) Yoshida, S.; Shimomori, K.; Kim, Y.; Hosoya, T. Single C–F Bond Cleavage of Trifluoromethylarenes with an ortho-Silyl Group. *Angew. Chem., Int. Ed.* **2016**, *55*, 10406–10409. (c) Mallov, I.; Ruddy, A. J.; Zhu, H.; Grimme, S.; Stephan, D. W. C–F Bond Activation by Silylium Cation/Phosphine Frustrated Lewis Pairs: Mono-Hydrodefluorination of PhCF₃, PhCF₂H and Ph₂CF₂. *Chem. - Eur. J.* **2017**, *23*, 17692–17696. (d) Mandal, D.; Gupta, R.; Jaiswal, A. K.; Young, R. D. Frustrated Lewis-Pair-Mediated Selective Single Fluoride Substitution in Trifluoromethyl Groups. *J. Am. Chem. Soc.* **2020**, *142*, 2572–2578.

(6) (a) Munoz, S. B.; Ni, C.; Zhang, Z.; Wang, F.; Shao, N.; Mathew, T.; Olah, G. A.; Prakash, G. K. S. Selective Late-Stage Hydrodefluorination of Trifluoromethylarenes: A Facile Access to Difluoromethylarenes. *Eur. J. Org. Chem.* **2017**, *2017*, 2322–2326. (b) Dang, H.; Whittaker, A. M.; Lalic, G. Catalytic activation of a single C–F bond in trifluoromethyl arenes. *Chem. Sci.* **2016**, *7*, 505–509.

(7) (a) Vogt, D. B.; Seath, C. P.; Wang, H.; Jui, N. T. Selective C–F Functionalization of Unactivated Trifluoromethylarenes. *J. Am. Chem. Soc.* **2019**, *141*, 13203–13211. For seminal examples of photoredox catalyzed hydrodefluoroalkylation, see: (b) Wang, H.; Jui, N. T. Catalytic Defluoroalkylation of Trifluoromethylaromatics with Unactivated Alkenes. *J. Am. Chem. Soc.* **2018**, *140*, 163–166. (c) Chen, K.; Berg, N.; Gschwind, R.; König, B. Selective Single C(sp³)-F Bond Cleavage in Trifluoromethylarenes: Merging Visible-Light Catalysis with Lewis Acid Activation. *J. Am. Chem. Soc.* **2017**, *139*, 18444–18447.

(8) (a) Pan, Y. The Dark Side of Fluorine. *ACS Med. Chem. Lett.* **2019**, *10*, 1016–1019. (b) Tuan, E.; Kirk, K. L. Fluorine reactivity in difluoromethylimidazoles. *J. Fluorine Chem.* **2006**, *127*, 980–982. (c) Woolridge, E. M.; Rokita, S. E. Synthesis and reactivity of 6-(fluoromethyl)indole and 6-(difluoromethyl)indole. *Tetrahedron Lett.* **1989**, *30*, 6117–6120.

(9) Fu, Y.; Lin, B. L.; Song, K. S.; Liu, L.; Guo, Q. X. Substituent effects on the S–H bond dissociation energies of thiophenols. *J. Chem. Soc., Perkin Trans. 2* **2002**, *7*, 1223–1230.

(10) Mohler, M. L.; Bohl, C. E.; Jones, A.; Coss, C. C.; Narayanan, R.; He, Y.; Hwang, D. J.; Dalton, J. T.; Miller, D. D. Nonsteroidal Selective Androgen Receptor Modulators (SARMs): Dissociating the Anabolic and Androgenic Activities of the Androgen Activities of the Androgen Receptor for Therapeutic Benefit. *J. Med. Chem.* **2009**, *52*, 3597–3617.

(11) Nair, V. A.; Mustafa, S. M.; Mohler, M. L.; Yang, J.; Kirkovsky, L. I.; Dalton, J. T.; Miller, D. D. Synthesis of irreversibly binding

bicalutamide analogs for imaging studies. *Tetrahedron Lett.* **2005**, *46*, 4821–4823.

(12) Macfarlane, T. V.; Pigazzani, F.; Flynn, R. W. V.; MacDonald, T. M. The effect of indapamide vs. Bendroflumethiazide for primary hypertension: a systematic review. *Br. J. Clin. Pharmacol.* **2019**, *85*, 285–303.

(13) Li, X. T.; Gu, Q. S.; Dong, X. Y.; Meng, X.; Liu, X. Y. A Copper Catalyst with a Cinchona-Alkaloid-Based Sulfonamide Ligand for Asymmetric Radical Oxytrifluoromethylation of Alkenyl Oximes. *Angew. Chem., Int. Ed.* **2018**, *57*, 7668–7672.

(14) Ito, Y.; Sadar, M. D. Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens. *Res. Rep. Urol.* **2018**, *10*, 23–32.

(15) Rozzell, J. D.; McCague, R. Selective androgen receptor modulators. US 7205437 B2, April 17, 2007.

(16) For further details, see [Supporting Information](#).

(17) Using the optimized conditions by Jui and co-workers (ref 7b), **14b** was obtained in 4% yield and a selectivity of 2:1 (¹⁹F NMR). The conditions of Prakash and co-workers (ref 6a) and Lalic and co-workers (ref 6b) did not afford **14b**. The starting materials were recovered.

(18) (a) Collins, K. D.; Glorius, F. A robustness screen for the rapid assessment of chemical reactions. *Nat. Chem.* **2013**, *5*, 597–601.

(b) Collins, K. D.; Rühling, A.; Glorius, F. Application of a robustness screen for the evaluation of synthetic organic methodology. *Nat. Protoc.* **2014**, *9*, 1348–1353. (c) Collins, K. D.; Rühling, A.; Lied, F.; Glorius, F. Rapid Assessment of Protecting-Group Stability by Using a Robustness Screen. *Chem. - Eur. J.* **2014**, *20*, 3800–3805. (d) Taylor, N. J.; Emer, E.; Preshlock, S.; Schedler, M.; Tredwell, M.; Verhoog, S.; Mercier, J.; Genicot, C.; Gouverneur, V. Derisking the Cu-Mediated ¹⁸F-Fluorination of Heterocyclic Positron Emission Tomography Radioligands. *J. Am. Chem. Soc.* **2017**, *139*, 8267–8276. (e) Gensch, T.; Teders, M.; Glorius, F. Approach to Comparing the Functional Group Tolerance of Reactions. *J. Org. Chem.* **2017**, *82*, 9154–9159.

(19) Vitaku, E.; Smith, D. T.; Njardarson, J. T. Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals. *J. Med. Chem.* **2014**, *57*, 10257–10274.

(20) Crabtree, R. H. Deactivation in homogeneous transition metal catalysis: causes, avoidance, and cure. *Chem. Rev.* **2015**, *115*, 127–150.

(21) (a) Fier, P. S.; Hartwig, J. F. Copper-mediated difluoromethylation of aryl and vinyl iodides. *J. Am. Chem. Soc.* **2012**, *134*, 5524–5527. (b) Prakash, G. K. S.; Ganesh, S. K.; Jones, J. P.; Kulkarni, A.; Masood, K.; Swabeck, J. K.; Olah, G. A. Copper-Mediated Difluoromethylation of (Hetero) aryl Iodides and β-Styryl Halides with Tributyl (difluoromethyl) stannane. *Angew. Chem., Int. Ed.* **2012**, *51*, 12090–12094. (c) Matheis, C.; Jouvin, K.; Goossen, L. J. Sandmeyer difluoromethylation of (hetero-)arenediazonium salts. *Org. Lett.* **2014**, *16*, 5984–5987. (d) Lu, C.; Gu, Y.; Wu, J.; Gu, Y.; Shen, Q. Palladium-catalyzed difluoromethylation of heteroaryl chlorides, bromides and iodides. *Chem. Sci.* **2017**, *8*, 4848–4852. (e) Bacauanu, V.; Cardinal, S.; Yamauchi, M.; Kondo, M.; Fernández, D. F.; Remy, R.; MacMillan, D. W. C. Metallaphotoredox Difluoromethylation of Aryl Bromides. *Angew. Chem., Int. Ed.* **2018**, *57*, 12543–12548. (f) Fu, X. P.; Xiao, Y. L.; Zhang, X. Nickel-Catalyzed Difluoromethylation of Arylboronic Acids with Bromodifluoromethane. *Chin. J. Chem.* **2018**, *36*, 143–146. (g) Sap, J. B. I.; Wilson, T. C.; Kee, C. W.; Straathof, N. J. W.; am Ende, C. W.; Mukherjee, P.; Zhang, L.; Genicot, C.; Gouverneur, V. Synthesis of ¹⁸F-difluoromethylarenes using aryl boronic acids, ethyl bromofluoroacetate and [¹⁸F]fluoride. *Chem. Sci.* **2019**, *10*, 3237–3241.

(22) (a) Cambié, D.; Bottecchia, C.; Straathof, N. J. W.; Hessel, V.; Noël, T. Applications of Continuous-Flow Photochemistry in Organic Synthesis, Material Science, and Water Treatment. *Chem. Rev.* **2016**, *116*, 10276–10341. (b) Plutschack, M. B.; Correia, C. A.; Seeberger, P. H.; Gilmore, K. Organic Photoredox Chemistry in Flow. *Top. Organomet. Chem.* **2015**, *57*, 43–76. (c) Rehm, T. H. Photochemical

Fluorination Reactions - A Promising Research Field for Continuous-Flow Synthesis. *Chem. Eng. Technol.* **2016**, *39*, 66–80. For a personal account on continuous flow photochemistry, see: (d) Gilmore, K.; Seeberger, P. H. Continuous Flow Photochemistry. *Chem. Rec.* **2014**, *14*, 410–418. (e) Sambiagio, C.; Noel, T. Flow Chemistry: Shine Some Light on Those Tubes! *Trends Chem.* **2020**, *2*, 92–106.

(23) Luo, J.; Zhang, J. Donor-Acceptor Fluorophores for Visible-Light-Promoted Organic Synthesis: Photoredox/Ni Dual Catalytic C(sp³)-C(sp²) Cross-Coupling. *ACS Catal.* **2016**, *6*, 873–877.

(24) Romero, N. A.; Nicewicz, D. A. Mechanistic Insight into the Photoredox Catalysis of Anti-Markovnikov Alkene Hydrofunctionalization Reactions. *J. Am. Chem. Soc.* **2014**, *136*, 17024–17035.

(25) The addition of the fluorophilic additive HBPIn was not beneficial for our process.

(26) This photocatalyst provides just enough ‘under potential’ to control selectivity. For a useful discussion, see: Lu, J.; Khetrpal, N. S.; Johnson, J. A.; Zeng, X. C.; Zhang, J. ‘ π -Hole- π ’ Interaction Promoted Photocatalytic Hydrodefluorination via Inner-Sphere Electron Transfer. *J. Am. Chem. Soc.* **2016**, *138*, 15805–15808.